UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erfolgreicher durch Networking in der Brustkrebstherapie

Best practice onkologie, 2019-11, Vol.14 (11), p.496-501

Jackisch, C.

2019

Volltextzugriff (PDF)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

British journal of cancer, 2013-09, Vol.109 (6), p.1556-1561

2013

Volltextzugriff (PDF)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

Krebsprävention heute: von der Theorie zur praktischen Umsetzung

Der Onkologe, 2022, Vol.28 (1), p.55-61

2022

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Annals of oncology, 2022-11, Vol.33 (11), p.1149-1158

2022

Volltextzugriff (PDF)

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Annals of oncology, 2013-11, Vol.24 (11), p.2786-2793

2013

Volltextzugriff (PDF)

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Annals of oncology, 2020-09, Vol.31 (9), p.1216-1222

2020

Volltextzugriff (PDF)

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Annals of oncology, 2021-01, Vol.32 (1), p.49-57

2021

Volltextzugriff (PDF)

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

Annals of oncology, 2015-02, Vol.26 (2), p.320-325

2015

Volltextzugriff (PDF)

HESS Opinions: From response units to functional units: a thermodynamic reinterpretation of the HRU concept to link spatial organization and functioning of intermediate scale catchments

Hydrology and earth system sciences, 2014-11, Vol.18 (11), p.4635-4655

2014

Volltextzugriff (PDF)

S3-Leitlinie: Endokrine Therapie des primären Mammakarzinoms

Gynäkologe (Berlin), 2018-07, Vol.51 (7), p.548-555

2018

Volltextzugriff (PDF)

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Annals of oncology, 2017-03, Vol.28 (3), p.497-504

2017

Volltextzugriff (PDF)

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Volltextzugriff (PDF)

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer

Annals of oncology, 2013-06, Vol.24 (6), p.1505-1512

2013

Volltextzugriff (PDF)

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

Annals of oncology, 2017-04, Vol.28 (4), p.754-760

2017

Volltextzugriff (PDF)

HER‐2‐Positive Metastatic Breast Cancer: Optimizing Trastuzumab‐Based Therapy

The oncologist (Dayton, Ohio), 2006-01, Vol.11 (S1), p.34-41

Jackisch, Christian

2006

Volltextzugriff (PDF)

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

Annals of oncology, 2014-01, Vol.25 (1), p.81-89

2014

Volltextzugriff (PDF)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

Annals of oncology, 2013-03, Vol.24 (3), p.618-624

2013

Volltextzugriff (PDF)

Subcutaneous Administration of Monoclonal Antibodies in Oncology

Geburtshilfe und Frauenheilkunde, 2014-04, Vol.74 (4), p.343-349

2014

Volltextzugriff (PDF)

P262 How patients prioritize features of different potential treatment pathways in early breast cancer: a best-worst scaling study

Breast (Edinburgh), 2023-04, Vol.68, p.S119-S120

2023

Volltextzugriff (PDF)

Predictive molecular diagnostics in breast cancer : What are the requirements for pathology today and in the future?

Pathologie (Heidelberg, Germany), 2022-09, Vol.43 (5), p.388-398

2022

Volltextzugriff (PDF)

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

Annals of oncology, 2019-05, Vol.30, p.iii38-iii38

2019

Volltextzugriff (PDF)

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

Annals of oncology, 2014-02, Vol.25 (2), p.372-377

2014

Volltextzugriff (PDF)

1 – 25 von 574

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(531)
Mit Volltextzugriff
(489)

Publikationsform

Sprache

Englisch
(465)
Deutsch
(115)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(177)
Life Sciences & Biomedicine
(161)
Female
(130)
Humans
(120)
Biological And Medical Sciences
(91)
Oncology
(91)
Middle Aged
(76)
Adult
(63)
Aged
(61)
Medical Sciences
(60)
Breast Cancer
(56)
Animals
(52)
Breast Neoplasms - Drug Therapy
(50)
Tumors
(42)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(39)
Rats
(38)
Breast Neoplasms - Pathology
(34)
Obstetrics & Gynecology
(33)
Gynecology. Andrology. Obstetrics
(32)
Neurosciences
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Erfolgreicher durch Networking in der Brustkrebstherapie

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Krebsprävention heute: von der Theorie zur praktischen Umsetzung

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

HESS Opinions: From response units to functional units: a thermodynamic reinterpretation of the HRU concept to link spatial organization and functioning of intermediate scale catchments

S3-Leitlinie: Endokrine Therapie des primären Mammakarzinoms

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

HER‐2‐Positive Metastatic Breast Cancer: Optimizing Trastuzumab‐Based Therapy

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

Subcutaneous Administration of Monoclonal Antibodies in Oncology

P262 How patients prioritize features of different potential treatment pathways in early breast cancer: a best-worst scaling study

Predictive molecular diagnostics in breast cancer : What are the requirements for pathology today and in the future?

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288]

GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy

Suchergebnisse filtern